New study tracks epidiolex use in pregnancy for baby safety

NCT ID NCT06113237

Recruiting now Knowledge-focused Sponsor: Jazz Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 24, 2026 · Updated 4 times

Summary

This study follows pregnant women who have taken Epidiolex (a cannabidiol medicine for seizures) to see if it affects pregnancy outcomes or the baby's health up to 12 months after birth. Researchers will track complications like birth defects, miscarriage, and preterm delivery. The goal is to better understand any risks, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Epidiolex (cannabidiol oral solution)
What this could lead to: If successful, this study could provide important safety information about using Epidiolex during pregnancy, helping doctors and patients make informed decisions.
What could go wrong: This is an observational study with only 50 participants, so results may not apply to everyone. It is designed to gather data, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BIRTH OUTCOMES, ADVERSE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pregnancy disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BIRTH OUTCOMES, ADVERSE MATERNAL COMPLICATIONS PREGNANCY PREGNANCY COMPLICATION

Contacts and locations

Locations

United Biosource LLC
RECRUITING

Morgantown, West Virginia, 26508, United States
Vivantes Humboldt-Klinikum Klinik für Neurologie
RECRUITING

Berlin, 13509, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.